Experience of Rituximab Treatment in Two Patients with Severe Systemic Lupus Erythematosus.
- Author:
Ki Won HWANG
1
;
Yong Sung AHN
;
Ji Yoon MOON
;
Il Young KIM
;
Young Eun PARK
;
Geun Tae KIM
;
Jun Hee LEE
;
Sung Il KIM
Author Information
1. Department of Internal Medicine, Pusan National University College of Medicine, Korea. ksimd@pusan.ac.kr
- Publication Type:Case Report
- Keywords:
Rituximab;
Systemic lupus erythematosus
- MeSH:
Acute Kidney Injury;
Adolescent;
Adult;
Anemia, Hemolytic;
Arthritis, Rheumatoid;
Autoimmune Diseases;
Female;
Fetal Membranes, Premature Rupture;
Hemorrhage;
Humans;
Lupus Erythematosus, Systemic*;
Lupus Nephritis;
Lymphocyte Subsets;
Pregnancy;
Rituximab;
Thrombocytopenia
- From:The Journal of the Korean Rheumatism Association
2006;13(3):230-235
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Rituximab is a chimeric monoclonal antibody for human B lymphocyte subset CD20 and has recently been used for treatment of autoimmune disease such as rheumatoid arthritis and systemic lupus erythematosus (SLE). We report the experiences of rituximab treatment in two patients with severe SLE. The first case is 16-year-old female patient with hemolytic anemia, thrombocytopenia and acute renal failure due to aggravation of lupus nephritis, and the second case is 30-year-old female pregnant patient with diffuse alveolar hemorrhage after preterm premature rupture of fetal membranes. All two patients responded to rituximab and maintained symptom free state.
